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The TGF-b pathway plays a central role in tissue homeostasis and morphogenesis. It transduces a variety of
extracellular signals into intracellular transcriptional responses that control a plethora of cellular processes, including
cell growth, apoptosis, and differentiation. We use computational modeling to show that coupling of signaling with
receptor trafficking results in a highly versatile signal-processing unit, able to sense by itself absolute levels of ligand,
temporal changes in ligand concentration, and ratios of multiple ligands. This coupling controls whether the response
of the receptor module is transient or permanent and whether or not different signaling channels behave
independently of each other. Our computational approach unifies seemingly disparate experimental observations and
suggests specific changes in receptor trafficking patterns that can lead to phenotypes that favor tumor progression.
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Introduction
The TGF-b signal transduction pathway follows an appa-
rently straightforward downstream cascade, progressing
sequentially from the interaction of ligands with trans-
membrane receptors, through phosphorylation of mediator
Smad proteins, to transcriptional responses (Figure 1). The
simple logic of this signal transduction cascade strongly
contrasts with the molecular complexity of the cellular
processes involved and the wide diversity of responses
triggered.
At the molecular level, there is an intricate signal trans-
duction machinery that integrates signals from the 42 known
ligands of the TGF-b superfamily, funnels them through the
two principal regulatory Smad (R-Smad) channels (Smad1/5/8
or Smad2/3), and subsequently leads to the widespread
transcriptional control of more than 300 target genes in a
cell-context dependent manner [1] (see Figure 2). The
components of this machinery include the members of the
two main receptor families (type I and type II receptors), a
myriad of adaptor proteins, and the trafﬁcking apparatus of
the cell, which shuttles proteins between different subcellular
compartments. Each ligand induces the formation of a
receptor complex with type I and type II receptors, which
then signal through one of the two Smad channels [2,3]. The
ability of most ligands to bind several type I and type II
receptors results in a complex ligand-receptor interaction
network (Figure 2).
At the phenotypic level, the responses are extremely
diverse. The members of the TGF-b superfamily act proto-
typically as potent negative growth regulators, but, depending
on the cell type and context, they can also induce differ-
entiation, apoptosis, cell migration, adhesion, and extracel-
lular matrix deposition. TGF-b itself is of particular interest
in cancer research. In epithelial cells, it suppresses cellular
growth by inducing G1 arrest (mediated by transcriptional
activation of p15 and p21) [4], and its inactivation contributes
to tumorigenesis. The versatility of the pathway in eliciting
different types of behavior is perhaps best epitomized by the
pervasive, rather paradoxical ability of TGF-b to change its
function from suppressor to promoter of growth in epithelial
cells during tumor progression [4,5].
Current theories for explaining the variety of responses to
members of the TGF-b superfamily of ligands focus mainly on
the downstream transcriptional regulatory networks they
activate: transcriptional cofactors of the R-Smads are ex-
pressed at different levels in a cell-speciﬁc manner, thereby
modifying downstream responses. In fact, the role reversal of
TGF-b from negative to positive growth regulator has been
found to be associated with a phenotypic change known as
epithelial-to-mesenchymal transition, in which cells change
the cofactors recruited by the R-Smads and acquire motile
phenotypes [5–7].
It is striking, however, that such a variety of complex
responses and intricate molecular components are connected
through just two Smad channels by such a simple downstream
signal transduction cascade. There is a richness of exper-
imental observations that are difﬁcult to reconcile with this
observation. In particular, whether TGF-b acts as a growth
suppressor or promoter can depend on whether the tumor
cells were grown in vitro or in vivo [8]. In these two different
situations, the extracellular context determines the way in
which cells respond to TGF-b. It has been suggested that TGF-
b can suppress the growth of cells around the tumor, that it
can shut down locally the immune system, and that it can
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the growth of the tumor in vivo, where it has to compete with
neighboring cells. So far, although appealing, none of these
mechanisms has been identiﬁed as an alternative cause of the
TGF-b role reversal.
The most direct way in which the extracellular context can
affect the functioning of the TGF-b pathway is through
signaling of other ligands of the TGF-b superfamily. As we
have mentioned, ligands and receptors form a complex
interaction network, where multiple ligands share receptors,
potentially coupling their signaling. All these interactions are
in turn coupled to receptor trafﬁcking, which is known to be a
mechanism that regulates signal transduction [9,10]. Trafﬁck-
ing has been investigated in detail in many signal trans-
duction pathways, such as the epidermal growth factor
receptor (EGFR) and G protein-coupled receptor (GPCR)
pathways [11–13]. The typical way in which trafﬁcking and
signaling are coupled is by the induction of receptor
internalization upon ligand binding and receptor activation,
as for instance in the EGFR and GPCR pathways. After
internalization, receptors can activate other signaling path-
ways, be modiﬁed in speciﬁc ways, and be targeted for
degradation or recycling back to the plasma membrane.
A peculiarity of the TGF-b pathway is that receptors are
constitutively internalized, even in the absence of ligand
[14,15]. The trafﬁcking route that the receptors follow,
Figure 2. Interactions among the Ligands of the TGF-b Superfamily and
Their Receptors
The graphical representation lays out the specific type II/type I receptor
complexes that different ligands mediate (based on data reviewed in
reference[32]).EachsetoflinksdrawnbetweenatypeIIandtypeIreceptor,
mediated by a connecting ligand, represents a feasible ligand-receptor
complex. The 14 ligands, 5 type II and 7 type I receptors shown here give
rise to 50 different combinations of ligand-receptor complexes overall.
Note that many of these 50 complexes share ligand and receptor species.
The ligand-receptor complexes phosporylate the cytoplasmic R-Smads;
at this point the signal is essentially funneled into two different
pathways. The decision of which one is chosen depends on the particular
type I receptor in the ligand-receptor complex. The type I receptors can
be divided into two groups, depending on which subgroup of R-Smads
they bind and phosphorylate: the first group of type I receptors (Alk1/2/
3/6, shown on the bottom right) bind and activate the R-Smads Smad1/
5/8, whereas the second group (Alk4/5/7, shown on the top right) act on
the R-Smads Smad2/3. The phosphorylated R-Smads then form
complexes with the Co-Smad Smad4.
DOI: 10.1371/journal.pcbi.0020003.g002
Figure 1. Formation of Receptor Hetero-Tetramers
The active form of the TGF-b ligand is a dimer of two molecules held
together by hydrophobic interactions and a disulfide bond [30,31]. This
dimer induces the formation, at the plasma membrane, of receptor
hetero-tetramers that contain two type I and two type II receptors [2,3].
The type II receptors phosphorylate the type I receptors; the type I
receptors are then enabled to phosphorylate cytoplasmic R-Smads,
which then act as transcriptional regulators.
DOI: 10.1371/journal.pcbi.0020003.g001
PLoS Computational Biology | www.ploscompbiol.org January 2006 | Volume 2 | Issue 1 | e3 0037
Synopsis
Sensing of the environment by cells relies extensively on receptors
that bind extracellular molecules and trigger intracellular responses.
The TGF-b pathway transduces a broad range of extracellular signals
into transcriptional responses that affect many cellular processes,
including cell growth, apoptosis, differentiation, homeostasis, and
morphogenesis. It is used, for instance, to control the precise
patterns and forms that arise during development, and its
malfunction contributes to a wide variety of diseases and
developmental disorders. Here the authors develop a concise
computational model of the TGF-b pathway and show that the first
layer of communication with the environment, the ligand-receptor
network, is not merely a passive transducer of signals but rather
embeds properties that makes it a signal processing unit. Receptors
traffic between different cellular compartments from which they
signal distinctly, leading to an unexpected richness of types of
behavior that is not apparent from the simplicity of the typical
cartoon representations of this pathway. At the receptor level, the
system can select among different functioning modes to sense
absolute levels of ligand, temporal changes in ligand concentration,
and ratios of multiple ligands. This extra level of regulation can
explain a wide variety of phenomena and leads to a unified
interpretation of seemingly disparate experimental observations.
Signal Processing in the TGF-b Pathwayhowever, depends on whether or not they are in a signaling
complex (Figure 3). Different routes will trigger different
signaling outcomes and affect how receptors are degraded.
Therefore, although the explicit implementation of the
coupling is different than in the EGFR and GPCR pathways,
receptor trafﬁcking and signaling are also tightly coupled in
the TGF-b pathway.
Taking all the current experimental data together, it is
clear that many details of the underlying processes remain
largely unknown. Recent experiments [14,15], however,
provide key information that allows computational modeling
to bridge the gap between potential molecular mechanisms
and experimentally observable behavior. The TGF-b pathway
is at a discovery stage where modeling can help to gain
‘‘functional’’ intuition.
Here we characterize computationally the diverse potential
types of behavior that the pathway structure itself can confer
on the system. The types of behavior include responses to
persistent changes in ligand concentration that can be
transient or sustained and simultaneous responses to multi-
ple ligands that can be passed downstream independently of
or dependently on each other.
A sustained response implies that the steady-state signaling
activity is a function of the ligand concentration. In this case,
the higher the ligand concentration, the higher the activity of
the pathway. For a transient response that precisely returns
to the prestimulus level, in contrast, the steady-state activity is
always the same and the pathway can only detect changes in
ligand concentration. When multiple ligands signal in a
dependent fashion, the extent of the coupling can be such
that one ligand can suppress the effects of another one. In
this regime, the pathway does not detect ligand concen-
trations but ratios of concentrations.
As we show here, all these types of behavior can be present
in the TGF-b pathway. Which speciﬁc one is selected is
determined by the interplay between trafﬁcking and signal-
ing. Thus the pathway can be set to detect, at the receptor
level, absolute levels of ligand, temporal changes in ligand
concentration, and ratios of multiple ligands. Such ﬂexibility
in the pathway behavior can lead to diverse physiological
outcomes that have been associated with facilitated tumor
progression.
Results
A Concise Computational Model
In order to study the signal processing potential of the
ligand-receptor network coupled with receptor trafﬁcking,
we assemble all the essential elements into a concise
mathematical model that captures the logic of the underlying
processes. The main goal is to represent as much complexity
as possible through a small number of quantities that have
direct experimental interpretation.
The essential elements we consider are (Figure 4): (i)
Ligands induce the formation of receptor complexes with
type II and type I receptors. (ii) Receptors and ligand-
receptor complexes can be present in two spatially distinct
compartments: plasma membrane and internalized endo-
somes. (iii) The signaling activity is proportional to the
number of ligand-receptor complexes that are present in the
internalized endosomes [16]. (iv) Receptors and ligand-
receptor complexes are continuously internalized into endo-
somes and recycled back to the plasma membrane [14, 15]. (v)
Receptor degradation has a constitutive contribution, which
is the same for free receptors and ligand-receptor complexes
[14,15]. (vi) Receptor degradation has a ligand-induced
contribution, which affects only receptors that have been
complexed with ligands [14,15].
We use these elements to develop a mathematical model
based on rate equations that describe the dynamics of both
how different molecular species transform into each other
and how they trafﬁc between the different cellular compart-
ments. We assume that internalization, recycling, and
degradation rates are proportional to the number of
receptors or ligand-receptor complexes; and that the
formation of ligand-receptor complexes is proportional to
the ligand concentration and to the type I and type II
receptor concentrations.
In a ﬁrst step toward characterizing the effects of the
coupling of signaling with receptor trafﬁcking, we consider
that only a single type of ligand is present. Explicitly, we study
how the components of the canonical TGF-b pathway—one
Figure 3. Signaling and Trafficking in the TGF-b Pathway
Receptors in the plasma membrane interact with the signaling peptides
of the TGF-b superfamily to form active complexes. Receptors and
activated ligand-receptor complexes can internalize via clathrin-coated
pits into endosomes, from where the active ligand-receptor complexes
phosphorylate the cytoplasmic R-Smads (‘‘receptor Smads,’’ either the
Smad1/5/8 or the Smad2/3 group) [33].
The phosphorylated R-Smads form complexes with the Co-Smad
(Smad4) and then translocate into the nucleus where they act as
transcriptional regulators of about 300 target genes.
The internalized receptors recycle back to the plasma membrane (with a
characteristic time of ;30 min) via a rab11-dependent, rab4-independ-
ent pathway [14]. After returning to the plasma membrane, the receptors
that were actively signaling can be targeted for degradation or be used
for further ligand-binding or internalization [14]. Receptors that did not
bind ligands are simply returned to the plasma membrane. As a
consequence of the trafficking processes, only about 5%–10% of
receptors are present in the plasma membrane [15].
In addition to the traditional clathrin pathway, active ligand-receptor
complexes can recruit Smad7-Smurf2 [28], which then targets them to
lipid raft–caveolar compartments (right) for degradation [15].
The ligands do not return back to the plasma membrane, but
disassociate from the receptors before recycling and undergo direct
degradation via the lysosomes [14].
Note that, in addition to the ligand-induced receptor degradation, we
also consider a receptor degradation pathway that functions independ-
ently of ligand-binding; this represents a ‘‘constitutive’’ or ligand-
independent degradation pathway (left).
DOI: 10.1371/journal.pcbi.0020003.g003
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Signal Processing in the TGF-b Pathwayligand (TGF-b) and two receptors (Alk5 and TGFbRII), as
emphasized in Figure 2—respond to changes in ligand
concentration. The mathematical equations are shown in
Figure 4. For typical trafﬁcking rates (see Materials and
Methods), this model closely reproduces the typical time
courses of Smad phosphorylation upon addition of ligand
(Figure 5A and 5B).
The computational model can be used also to analyze how
different parameters affect the behavior of the system. For
instance, the time during which the signaling activity rises is
related to the time required for internalization and recycling
of the receptors. Thus, the signal will peak, or stop rising, at
about 30–60 min after ligand addition. If the internalization
and recycling rates are changed, the position of the peak
changes accordingly (Figure 5C and 5D).
Other transmembrane receptor pathways, such as the
EGFR pathway, have much faster kinetics; the EGFR pathway
reaches peak activity as fast as 5 min after stimulation [17].
The main reason for these differences is that most of the EGF
receptors are present in the plasma membrane and they are
ready to signal upon the addition of ligand. A similar kinetics
is also observed for many GPCRs. In the TGF-b pathway,
Figure 4. Two-Compartment Model of Receptor Trafficking and Signaling
Graphical representation and equations for a model with one ligand that forms complexes with one type I and one type II receptor. Receptors are
present in two main compartments: the plasma membrane (receptors at the cell surface) and the endosomes (internalized receptors). Receptors and
ligand-receptor complexes traffic between these two compartments by internalization and recycling. Only internalized ligand-bound receptors have
kinase activity. Active receptors can also be internalized in a degradation pathway (right). In addition, receptors in the plasma membrane can undergo
constitutive degradation, independently of whether they are ligand-bound (left). A supply of new receptors is constantly produced by gene expression.
Theconcentrationoftheligandisdenotedby[l];thenumbersoftypeIandIIreceptorandligand-receptorcomplexesintheplasmamembrane,by[RI],[RII],
and [lR IRII], respectively; and the numbers of internalized type I and II receptor and ligand-receptor complexes by [RI], [RII], and [lRIRII], respectively. (Note
thattypeIIreceptorsarenotshowninthegraphicalrepresentation.)kaistherateconstantofligand-receptorcomplexformation;pRIandpRIIaretheratesof
receptorproduction;ki,k r,k cd,andklid aretheinternalization, recycling,constitutive degradation, andligand-induceddegradation rate constants; a is the
fraction of active receptors that are recycled back to the plasma membrane and can interact again with the ligand.
Thesignalingactivityofthepathwayisassumedtobeproportionaltothenumberofinternalizedligand-receptorcomplexes,[lRIRII].Thisassumptionisbasedon
theobservationsthatR-SmadproteinsbecomerapidlydephosphorylatedafterinhibitionofthereceptorkinaseactivityandthatnuclearSmadlocalizationclosely
follows Smad phosphorylation [16].
DOI: 10.1371/journal.pcbi.0020003.g004
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Signal Processing in the TGF-b Pathwayinternalization occurs continuously, and only about 5%–10%
of the receptors are present in the plasma membrane at a
given time [15]. The remaining 90%–95% of the receptors are
internalized in endosomes. Receptors need to be recycled
from the endosomes back to the plasma membrane in order
to be able to interact with the ligand; and this process takes
about 30 min on average.
We can use the computational model to study the effects of
different mechanisms, such as different forms of receptor
degradation, on the behavior of the system. It has been
observed that the addition of ligand can stimulate the
degradation of the receptors in two different ways. On the
one hand, receptors complexed with ligand in the plasma
membrane can be internalized through a lipid raft–caveolar
degradation pathway without becoming active signalers [15].
The behavior obtained in this case is the one we have already
described (Figure 5A). On the other hand, ligand-receptor
complexes can follow the standard internalization clathrin
pathway, signal, and then be targeted for degradation upon
returning to the plasma membrane [14]. Interestingly, when
this mechanism is explicitly modeled, the behavior obtained
(Figure5E)isqualitativelythesameasthepreviousone(Figure
5A). Likewise, when both degradation mechanisms are
consideredtogether,asimilartypeofbehavior isalsoobtained
(Figure 5F). Thus, at this level of detail and for this range of
parameter values, different mechanisms that implement
ligand-induced degradation can lead to similar behavior.
Control of the Signal: Transient versus Permanent
Responses
How is it possible to modify the form in which the system
responds to changes in TGF-b concentration? A mathemat-
ical analysis of the model (see below and Materials and
Methods for details) indicates that the key quantity that
determines the qualitative behavior of the pathway is the
ratio of the constitutive to the ligand-induced rate of
degradation, referred to, in short, as the constitutive-to-
induced degradation ratio (CIR). This quantity compares the
rates of two degradation processes and, in general, does not
have a simple expression in terms of rate constants.
Depending on the CIR, a permanent change in ligand
concentration can elicit responses between two extremes
(Figure 6). For low CIR, the ligand-induced degradation
process dominates and there is a transient increase in
signaling activity that returns to pre-stimulus levels (Figure
6A and 6B). For high CIR, the constitutive degradation
process dominates and there is a permanently elevated level
of signaling activity (Figure 6E and 6F).
For intermediate CIR, the behavior of the system is a
mixture of both limiting types of behavior, with transient and
permanent components (Figure 6C and 6D). The precise
parameter values inﬂuence the amplitude and characteristic
time of the response (see for instance Figure 5C and 5D), but
its qualitative shape, that is, whether the response is transient
(Figure 6A and 6B) or permanent (Figure 6E and 6F), depends
only on the CIR.
The intuitive explanation of such types of behavior is as
follows (for a detailed mathematical analysis, see Materials
and Methods). The probability for a receptor to bind the
ligand, and therefore to become active, increases with the
ligand concentration. If the ligand does not induce the
degradation of receptors, the number of receptors remains
Figure 5. Typical Time Courses of the Number of Active Receptor
Complexes upon Addition of TGF-b
The typical response to sustained changes in TGF-b concentration shows
partial adaptation after reaching a maximum of activity. Different values
of the parameters of the model lead to this characteristic behavior. In all
panels, the TGF-b concentration is increased at time 0 to saturating
values and kept constant afterward, as in inset in (A).
(A) Behavior of the model for typical trafficking rates: internalization, ki¼
(3 min)
 1; recycling, kr ¼ (30 min)
 1; constitutive degradation, kcd ¼ (36
min)
 1; ligand-induced degradation klid¼(4 min)
 1; efficiency of recycling
of active receptors, a ¼ 1. Note that the trafficking rate constants are
given as the inverse of the corresponding characteristic times. The
production of receptors is chosen to be pRI¼8 min
 1 and pRII¼4 min
 1,
which leads to ;10
3 receptors per cell under stationary conditions in the
absence of ligand. The units of ligand concentration are chosen so that
the association rate constant is the unit, ka¼1. For these units, EC50 ’ 2
310
 4. At time 0, the ligand concentration changes from 3310
 5 to 0.01.
The signal peaks at ;60 min.
(B)Comparisonofthemodeltimecourse(upperlane)withanexperimental
time course of nuclear phosphorylated Smad2 (P-Smad) as reported by
Inmanetal.(bottomlane)[16].Themodelresultsfrom(A)areshownatthe
experimental time points and color-coded to ease comparison.
(C) Behavior of the model with the same parameter values as in (A), with
the exception of the rate constants for internalization and recycling that
have been decreased to ki ¼ (10 min)
 1 and kr ¼ (100 min)
 1. The signal
peaks at ;180 min.
(D) Behavior of the model with the same parameter values as in (A), with
the exception of the rate constants for internalization and recycling that
have been increased to ki ¼ (1 min)
 1 and kr ¼ (10 min)
 1. The signal
peaks at ;20 min.
(E) Behavior of the model with the same parameter values as in (A), with
the exception of the rate constant for ligand-induced degradation that
has been decreased to klid ¼ 0 and the efficiency of recycling of active
receptors that has been decreased to a ¼ 0.5. This implies that ligand-
receptor complexes are not degraded via the caveolae pathway. In
contrast, 50% of the active ligand-receptors that come back to the
plasma membrane after they have signaled are degraded.
(F)Behaviorofthemodelwiththesameparametervaluesasin(A),withthe
exception of the efficiency of recycling of active receptors that has been
decreased to a¼0.5. These parameters account for both types (caveola-
dependent and recycling-dependent) of ligand-induced degradation.
DOI: 10.1371/journal.pcbi.0020003.g005
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Signal Processing in the TGF-b Pathwayconstant and the total activity increases when the ligand
concentration increases. If the ligand induces the degrada-
tion of the receptors, the number of receptors starts to
decrease after ligand addition, which will eventually attenuate
the signal. At steady state, the production and degradation of
receptors equal each other. In the limit of the CIR going to 0,
the signal adapts completely because degradation is propor-
tional to the activation of receptors, and therefore activation
is also proportional to the production of receptors. Thus, it is
the receptor production rate, not the ligand concentration,
that determines the steady-state signaling activity.
There are clear examples in other signal transduction
pathways that show that these two limiting types of behavior
can potentially lead to different physiological outcomes. For
instance, transient activation of the MAPK cascade by EGF
leads to cell proliferation. In contrast, permanent activation
of the MAPK cascade by NGF leads to cell differentiation. In
both cases, activation of the MAPK cascade induces the
expression of a negative regulator that shuts down the activity
of this cascade. The differences between EGF and NGF have
been attributed to additional pathways activated by NGF that
can prevent the inactivation of the MAPK cascade [18]. Our
model shows that such transient and permanent types of
behavior can also be achieved by just changing the trafﬁcking
patterns, in particular by adjusting the CIR, without the need
for explicitly expressing a negative regulator to shut down the
cascade after signaling.
Remarkably, the duration of the signaling activity also
seems to affect the physiological outcomes triggered by TGF-
b [19]. Epithelial cells that are sensitive to the antiprolifer-
ative effects of TGF-b (HaCaT and Colo-357) have sustained
activity of more than 6 h. In contrast, pancreatic tumor cell
lines (PT45 and Panc-1) show short transient activity of about
1–2 h. Such a short transient confers resistance to the
antiproliferative effects of TGF-b but maintains other
responses to TGF-b that can lead to increased malignancy
and invasiveness [19]. In our model, those differentiated types
of behavior arise naturally for different trafﬁcking patterns.
In particular, short transients and sustained responses imply
a low and a high CIR, respectively.
Control of the Signals: Coupled versus Uncoupled
Channels
In vivo conditions, in contrast to those typical of in vitro
experiments, expose cells to complex environments with
many different growth factors. When multiple ligands of the
TGF-b superfamily are present at the same time, they are
likely to affect each other’s signaling (Figure 2). To study how
multiple simultaneous input signals are integrated into
coordinated transcriptional responses, we extend our com-
putational model to consider two ligands that signal through
two different type II receptors and a shared common type I
receptor (see Materials and Methods for the mathematical
equations). This is the simplest case of signal integration.
Intuitively, one should expect signals to be coupled when
the shared receptor is saturated with ligands and uncoupled
when ligand concentrations are low. At saturation, increasing
the concentration of one ligand, and thus the concentration
of the corresponding ligand-receptor complex, will take the
shared receptor away from the complex formed by the other
ligand, thus decreasing its signaling.
A mathematical analysis of the model (see Materials and
Methods) indicates that even when the receptors are far from
ligand-saturating conditions, it is possible for signals to affect
each other. The key element is again receptor trafﬁcking. In
essence, the coupling arises because the induction of
degradation of the common receptor by one ligand attenu-
ates the effects of the other ligand, which also requires the
common receptor to transduce the signal.
For pathways working away from receptor saturation, the
interplay between trafﬁcking and signaling determines how
multiple simultaneous signals are passed downstream. As in
the single ligand case, there are two extreme types of
behavior (Figure 7): For low CIR, the ligand-induced
degradation process dominates and signals are completely
coupled (Figure 7A and 7B). For high CIR, the constitutive
degradation process dominates and signaling is uncoupled
(Figure 7E and 7F).
Figure 6. Control of the Kinetic Signaling Behavior
A key control quantity of the qualitative behavior of the system is the
CIR. Panels on the left (A, C, and E) show the typical behavior of the
system for different CIR values. The TGF-b concentration is increased at
time 0 to saturating values and remains constant afterward, (A) inset.
Panels on the right (B, D, and F) show the behavior of the system for the
same parameter values as the corresponding panels on the left but when
TGF-b concentration is increased slowly, (B) inset.
(A and B) Same parameter values as in Figure 5A with the exception that
the constitutive and ligand-induced degradation rates have been
decreased and increased by a factor three, respectively: kcd ¼ (3 3 36
min)
 1; ligand-induced degradation klid ¼ (4/3 min)
 1.
(C and D) Same parameter values as in Figure 5A. Figure in (C) is exactly
the same as Figure 5A.
(E and F) Same parameter values as in Figure 5A with the exception that
the constitutive and ligand-induced degradation rates have been
increased and decreased by a factor three, respectively: kcd ¼ (36/3
min)
 1; ligand-induced degradation klid ¼ (3 3 4 min)
 1.
DOI: 10.1371/journal.pcbi.0020003.g006
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Signal Processing in the TGF-b PathwayWhen the signals are completely coupled, the steady-state
number of all ligand-receptor complexes remains constant
and is independent of the ligand concentration. In this case,
increasing one signal will decrease the other one by the same
amount. When signals are uncoupled, the numbers of each
species of ligand-receptor complexes change independently
of each other. In general, for intermediate CIR, signals will
show some degree of coupling (Figure 7C and 7D). These
results demonstrate that changes in trafﬁcking patterns, and
the corresponding degradation, can alter the way in which
the pathway integrates multiple, simultaneous signals.
The completely coupled case is especially interesting
because it indicates that one ligand can potentially inhibit
the effects of another one. Ligand-induced degradation is
thus not only a mechanism for achieving transient responses,
but also for coupling multiple signals. The fact that TGF-b
can signal not only via Alk5 but also via Alk1 and Alk2 (Figure
2) potentially couples TGF-b signals to those of Activin A,
BMP 6, BMP 7, and MIS. Thus, if TGF-b loses its growth
suppressor properties, it could promote growth by inhibiting
other growth suppressor pathways. For instance, there are
dominant negative TGFbRII mutants that when overex-
pressed attenuate the response to TGF-b [20]. The presence
of any of these mutant receptors and TGF-b results in the
formation of futile receptor complexes that can target
receptors for degradation, or take receptors away, which
otherwise would be available to transduce the signals of other
members of the TGF-b superfamily.
Context-Dependent Response to TGF-b
The role reversal of TGF-b from negative to positive
growth regulator is a widespread feature of tumor progres-
sion and is often associated with endogenous overexpression
of TGF-b. As we have mentioned in the introduction, it is
associated in some situations with the epithelial-to-mesen-
chymal transition [6,7]. Under these conditions, the tran-
scriptional program of tumor cells changes so that the Smad-
activated genes promote rather than repress growth.
In other situations such a transition does not seem to be
present. It has been observed in breast, prostate, and colon
cancer cell lines that the action of TGF-b as growth promoter
or suppressor depends on whether the cells were grown in an
in vitro environment or in vivo in mouse xenografts [8,21,22].
The reasons for such a change remain largely unknown. It has
been speculated that it could be a consequence of the effects
of TGF-b on the in vivo microenvironment of the tumor cells.
Another possibility is that other growth factors, such as EGF,
affect how TGF-b is ultimately coupled to the cell cycle. Our
model explicitly shows that the role reversal is a potentially
intrinsic consequence of the design of the ligand-receptor
interaction network and trafﬁcking machineries and that it
could be the result of TGF-b attenuating the effects of
growth-suppressing signals of other members of the TGF-b
superfamily that might be present in the in vivo cell
environment.
Simultaneous Perfect Adaptation and Coupled Signaling
Our model also indicates that the conditions that give rise
to completely coupled integration of multiple signals are the
same that, in a single-ligand system, cause the signaling
activity to completely adapt to its prestimulus level.
Remarkably, this concurs with observations in prostate
cancer cell lines, which show that the in vivo context can
not only make TGF-b a growth promoter but also that the in
vitro response to TGF-b is transient [8]. One should expect
the extracellular environment of growth factors to be more
complex in vivo than in vitro. This relationship between in
vivo and in vitro behavior and its connection to the
coupling between receptor trafﬁcking and signaling under-
scores the importance of understanding how signal trans-
duction pathways are embedded within the cellular
microenvironment under physiologically relevant condi-
tions. Not only mutations in the canonical pathway but also
changes in trafﬁcking patterns can move the pathway to a
different functioning point.
The qualitative results of our model, such as the regimes
leading to transient and permanent responses as well as to
completely coupled and uncoupled modes of signal integra-
tion, do not depend on the details of the model but on
general properties (see Materials and Methods). Thus the
Figure 7. Control of Signal Integration
Time courses of the numbers of active receptor complexes when TGF-b
concentration (in red) is increased, repeatedly in steps or continuously.
Left panels (A, C, and E) show the responses to step increases as shown
in inset in (A). Right panels (B, D, and F) show the response to a
continuous increase as shown in inset in (B). There is also a second ligand
present (here BMP7, in blue) whose concentration is kept constant. The
two ligands induce the formation of two ligand-receptor complexes,
CBMP7 (blue) and CTGF-b (red), that share the type I receptor Alk2. The
green line on the left panels shows the total number of active receptor
complexes (CBMP7þCTGF b). As in Figure 6, a key control quantity of the
qualitative behavior of the system is the CIR. The parameter values for
(A–F) are the same as in Figure 6A–6F, respectively.
DOI: 10.1371/journal.pcbi.0020003.g007
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pathways that are coupled to receptor trafﬁcking. In
particular, revisiting the experimental data, one can see that
the interplay between adaptation and signal integration
(Materials and Methods) is also present in the EGFR pathway
(see Figures 4 and 5 of reference [23]), in which down-
regulation of erbB-2 by EGF concurs with adaptation of the
signal transmitted by EGFR.
Discussion
Cellular functions are controlled by networks of interact-
ing molecules that operate at different levels of organization
[24–26]. Here, we have developed a concise computational
model of the TGF-b pathway that shows that the receptors for
the TGF-b superfamily of ligands are not just passive signal
transducers. They are organized in a network that is able to
process the signals before passing them downstream. Changes
in receptor trafﬁcking patterns can modify the type of
behavior of the pathway in response to single and multiple
ligand inputs. Already at the receptor level, the pathway can
detect absolute levels of ligands, temporal changes in ligand
concentration, and ratios of multiple ligands. This extra level
of regulation can explain a wide variety of phenomena, such
as the counterintuitive role reversal of TGF-b from suppres-
sor to promoter of growth, and leads to a uniﬁed interpre-
tation of seemingly disparate experimental observations. A
key quantity that determines the qualitative behavior of the
pathway is the CIR of the receptors. For low CIR, the pathway
responds transiently to sustained changes in ligand concen-
tration, and the signaling activities of multiple simultaneous
ligands become dependent on each other. Ligand-induced
degradation is thus not only a mechanism for achieving
transient responses and perfect adaptation, but also for
coupling multiple signals.
Various experiments can be designed to test the predicted
types of behavior. The most direct evidence would come
from biochemical measurements of ligand-induced and
constitutive degradation rates [14,15]. The observed degra-
dation rates can then be related to measurements of the
levels of signaling activity. For instance, decreasing ligand-
induced degradation by blocking the lipid raft–caveolar
pathway with nystatin, as in reference [15], should bias the
system behavior toward permanent responses to step changes
in ligand concentration. Molecular interventions, such as
RNAi against the mRNA of proteins involved in the
trafﬁcking processes, and their effects on signaling activity
would provide indirect evidence that can be related to the
details of the model. Because of their well-established role in
intracellular trafﬁcking, small GTPase rab proteins [27] are
prime candidates for this type of approach. Certain
experimental observations [8,19] in conjunction with our
model suggest that cells with phenotypes that favor tumor
progression have low CIR. Further experiments could test the
extent of this correlation by comparing trafﬁcking rates and
signaling activity between different cancerous and non-
cancerous cell lines.
Materials and Methods
Internalization rate. It has been reported in Table 1 of reference
[15] that after 15 min of labeling the receptors at the plasma
membrane, only 8%, 6%, 4%, and 2% of the labeled receptors
remain at the plasma membrane (the different percentage values
correspond to different experimental conditions). The remaining
labeled receptors have been internalized in either caveolin-1 positive
or caveolin-1 negative vesicles. By using the formula ki ¼ 1
t lnft,
where ki is the internalization rate and ft the fraction of labeled
receptors that remain at the plasma membrane after a time t, we
obtain internalization rates of 1/5.9, 1/5.3, 1/4.7, and 1/3.8 min
 1,
respectively. We have chosen ki ¼ 1/(3 min) for comparison with
experimental data in Figure 5B.
Figure 4 of reference [14] shows that 1.7% of the total number of
receptors is internalized per minute. When this value is rescaled by
the fraction of receptors in the plasma membrane, it translates into
18% of surface receptors internalized per minute. This implies that
this internalization rate is ki ¼ 1/(5.3 min), which is similar to the
results obtained from reference [15]. The details of this rescaling are
as follows. Mathematically, the internalization rate constant is deﬁned
as ki ¼  1
Nsur
dNsur
dt , where Nsur is the number of receptors at the plasma
membrane. Mitchell et al. [14] measured kMitchell ¼  1
Ntot
dNsur
dt , where Ntot
is the total number of receptors. The fact that most of the receptors
are internalized, so that Nsur’0.1Ntot, leads to ki’10kMitchell The factor
0.1 results from the fact that the internalization rate is about 103
higher than the recycling rate. Therefore, under stationary con-
ditions, the number of internalized receptors is 103 higher than the
number of receptors at the plasma membrane.
Ligand-induced degradation rate. Active ligand-receptor com-
plexes in lipid raft–caveolar compartments can recruit Smad7-
Smurf2 [28], which then targets them for degradation [15]. Reference
[15] shows that receptors are internalized through the clathrin
pathway and lipid raft–caveolar compartments with similar rates. We
have chosen klid¼1/(4min) for comparison with experimental data in
Figure 5B.
Constitutive degradation rate. Figure 3 of reference [15] shows that
when the lipid raft–caveolar pathway is blocked with nystatin, only
;30%oftheinitiallylabeledreceptorsremaininthecellafter8h.This
givesacharacteristicdegradationtimeof;400minwithrespecttothe
total number of receptors. Rescaling this number to the plasma






Recycling rate. Figure 3 of reference [14] shows that after about 30
min cells stop secreting internally labeled TGF-b receptors. This
recycling rate is similar to that for the EGF receptor. We have chosen
kr ¼ 30 min for comparison with experimental data in Figure 5B.
Steady and quasi-steady state analysis. Here we study mathemati-
cally the properties of the steady state of the system with a single
ligand. By equating to 0 the derivatives in the model equations of





ka½l ½RI ½RII 
ðkcd þ klid þ kiÞ
; ð1Þ
where the steady-state number of type I and type II receptors at the
plasma membrane are obtained by solving the equations
0 ¼ aI   c½RI ½RII  ½ RI ;








; and c ¼
kcd þ klid þð 1   aÞki




The solution of these equations is
½RI ¼






















kikcdð1 þð aI þ aIIÞc  
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krðkcd þ klid þð 1   aÞkiÞ2c
ð5Þ
For low values of c, Equation 5 reduces to
½lRIRII  ¼
kikcdaIaIIc
krðkcd þ klid þð 1   aÞkiÞ
ð6Þ
which indicates that the steady-state number of internalized ligand-
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the production of each receptor type.
For high values of c, in contrast, we obtain
½lRIRII  ¼
kikcdaII
krðkcd þ klid þð 1   aÞkiÞ




krðkcd þ klid þð 1   aÞkiÞ
if aI   aII: ð8Þ
Therefore, for high ligand concentration or low constitutive
degradation, the steady-state number of internalized ligand-receptor
complexes is controlled by the receptor with the smallest production
rate and this number does not depend on the ligand concentration.
The case of high c and low constitutive degradation is especially
interesting because the steady-state signal does not depend on the
ligand concentration, even when the ligand is present in small
quantities. An important question to address now is: can the system
detect changes in concentration in this regime? When the recycling
rate is much lower than the internalization rate, the number of
ligand-receptor complexes in the plasma membrane equilibrates
faster than all the other variables. Therefore assuming quasi-
equilibrium in this variable, d
dt½lRIRII ¼0, we obtain that, upon
changes in the ligand concentration (D[l]), the changes in the number
of ligand-receptor complexes in the plasma membrane (D[lRIRII])
follow the equation
0 ¼ kað½l þD½l Þð½RI  D½lRIRII Þð½RII  D½lRIRII Þ
 ðkcd þ klid þ kiÞð½lRIRII þD½lRIRII Þ: ð9Þ
Note that we have assumed that the number of receptors in the
plasma membrane is conserved at these time scales.
For small changes in ligand concentration, we obtain
D½lRIRII ¼
kaD½l ½RI ½RII 
ka½l ð½RI þ½ RII Þ þ kcd þ klid þ ki
ð10Þ
This expression indicates that for high c, low constitutive degrada-
tion, and slow recycling (compared to internalization), the system can
detect changes in ligand concentration while keeping a steady-state
signal that does not depend on ligand concentration.
Two-compartment model of receptor trafﬁcking for two ligands.
The equations for a system with two ligands with concentrations [l1]
and [l2] and are:
d
dt
½l1RIRII;1 ¼ka½l1 ½RI ½RII;1  ð kcd þ klid þ kiÞ½l1RIRII;1 ð 11Þ
d
dt
½l2RIRII;2 ¼ka½l2 ½RI ½RII;2  ð kcd þ klid þ kiÞ½l2RIRII;2 ð 12Þ
d
dt
½RI ¼pRI   ka½l1 ½RI ½RII;1  ka½l2 ½RI ½RII;2  ð kcd þ kiÞ½RI 
þkr½RI  þakr½l1RIRII;1  þakr½l2RIRII;2  ð 13Þ
d
dt
½RII;1 ¼pRII;1   ka½l1 ½RI ½RII;1  ð kcd þ kiÞ½RII;1 þkr½RII;1  
þ akr½l1RIRII;1  ð 14Þ
d
dt
½RII;2 ¼pRII;2   ka½l2 ½RI ½RII;2  ð kcd þ kiÞ½RII;2 þkr½RII;2  
þ akr½l2RIRII;2  ð 15Þ
d
dt
½l1RIRII;1  ¼ki½l1RIRII;1  kr½l1RIRII;1   ð16Þ
d
dt
½l2RIRII;2  ¼ki½l2RIRII;2  kr½l2RIRII;2  ð 17Þ
d
dt
½RI  ¼ki½RI  kr½RI  ð 18Þ
d
dt
½RII;1  ¼ki½RII;1  kr½RII;1  ð 19Þ
d
dt
½RII;2  ¼ki½RII;2  kr½RII;2  ð 20Þ
The variables [RI], [RII,1], and [RII,2], are the numbers of type I and
type II receptors in the plasma membrane; and [l1RIRII,1] and
[l2RIRII,2] refer to the corresponding ligand-receptor complexes.
The overline indicates internalized receptors and ligand-receptor
complexes. The signaling activity triggered by each ligand is assumed
to be proportional to the corresponding number of internalized
ligand-receptor complexes. ka is the rate constant of ligand-receptor
complex formation; pRI, pRII,1, and pRII,2 are the rates of receptor
production; ki,k r,k cd, and klid, are the internalization, recycling,
constitutive degradation, and ligand-induced degradation rate con-
stants; and a is the fraction of active receptors that are recycled back
to the plasma membrane and can interact again with the ligand.
Coupled signaling and perfect adaptation. Computational model-
ing offers precise insights into the functioning of the TGF-b pathway.
It is possible to go a step further and generalize the conditions that
give rise to different qualitative types of behavior.
Let us consider two ligands (l1 and l2), one type I receptor (RI), and
two type II receptors (RII,1 and RII,2). The type I receptor is shared
among the two ligand-receptor complexes [l1 RI RII,1] and [l2 RI RII,2].
The following conservation equations refer to the common type I
receptor at steady-state.
Under stationary conditions, the number of receptors produced
(by gene expression) is equal to the number of receptors degraded:
p ¼ dconst þ dlid; ð21Þ
where p is the receptor production rate; and dconst and dlid are the
constitutive and ligand-induced degradation rates, respectively.
Assuming that a fraction d of the activated receptors is degraded
through a ligand-induced degradation process, we can express dlid as
dlid ¼ dðia1 þ ia2Þwithd 2ð 0;1Þ; ð22Þ
where ia1 and ia2 are the rates of formation of the ligand-receptor
complexes ([l1 RI RII,1] and [l2 RI RII,2], respectively). Therefore,
p ¼ dconst þ dðia1 þ ia2Þ: ð23Þ
We explicitly consider two limiting cases:
In the ﬁrst case, there is no ligand-induced degradation (dconst . 0, d¼
0). Therefore, we have dlid¼0, which leads to p¼dconst. Because dconst [
dconst(RT) is a function of the total number of receptors RT, the
previous condition indicates that the number of receptors remains
constant RT ¼ dconst
 1(p), where dconst
 1 is the inverse function of dconst.
For instance, if the constitutive receptor degradation follows ﬁrst
order kinetics, dconst¼cRT, then RT¼p/c. Under these conditions, if the
rate of formation of complexes (ia1þia2) is small (for instance, for low
ligand concentrations) compared with constitutive internalization
and degradation, there is no coupling between signaling channels.
In the second case, there is only ligand-induced degradation (dconst
¼0, d . 0). Therefore, we have p¼d (ia1þia2), which implies that the
formation of one ligand-receptor complex excludes the formation of
the other one. In this case, the number of receptors in the plasma
membrane does not remain constant, but is adjusted so that for a
given ligand concentration the rate of formation of complexes (ia1 þ
ia2) remains equal to p/d. As an explicit example, the kinetics ia1¼l1 RI
RII,1 and ia2 ¼ l1 RI RII,2 implies RI ¼ p/(l1 RII,1 þ l2 RII,2). Under these
conditions, the completely coupled mode of signal integration arises
even for low ligand concentrations.
The conditions that lead to the completely coupled mode of signal
integration also lead to perfect adaptation for a single ligand.
Consider, for example, ia2 ¼ 0. When there is only ligand-induced
degradation, the fact that the rate of formation of complexes remains
constant implies p ¼ dia1. The steady state of the system is ﬁxed
irrespective of the ligand concentration. Consequently, changes in
ligand concentration can only elicit transient responses that
completely adapt to the prestimulus level and the system exhibits
perfect adaptation [29].
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